BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21253782)

  • 1. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
    J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
    Gerlach M; Halley P; Riederer P; van den Buuse M
    J Neural Transm (Vienna); 2013 Jan; 120(1):31-6. PubMed ID: 22592937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
    Paquette MA; Martinez AA; Macheda T; Meshul CK; Johnson SW; Berger SP; Giuffrida A
    Eur J Neurosci; 2012 Nov; 36(9):3224-34. PubMed ID: 22861201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
    Bishop C; Krolewski DM; Eskow KL; Barnum CJ; Dupre KB; Deak T; Walker PD
    J Neurosci Res; 2009 May; 87(7):1645-58. PubMed ID: 19115412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Marin C; Aguilar E; Rodríguez-Oroz MC; Bartoszyk GD; Obeso JA
    Psychopharmacology (Berl); 2009 Jun; 204(2):241-50. PubMed ID: 19159919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
    Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    Bishop C; Taylor JL; Kuhn DM; Eskow KL; Park JY; Walker PD
    Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
    Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
    Pinna A; Costa G; Serra M; Contu L; Morelli M
    Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
    Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
    Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M; Beck J; Riederer P; van den Buuse M
    J Neural Transm (Vienna); 2011 Dec; 118(12):1727-32. PubMed ID: 21274579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
    Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
    Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.